Share: 
Status: 
Active
Rating: 
No votes yet
0

Webcast

Course description

If this is your first time accessing any of the Presentations from JADPRO Live at APSHO 2016, please take a moment to create an account using the Register link to the right. Otherwise, please log in with your username and password to proceed. Please contact ce@annenberg.net with any questions.

A continuing education activity for physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists.

This activity is supported by an unrestricted educational grant from Bristol-Meyers Squibb, Lilly USA, LLC, and Merck & Co.

Release date: January 17, 2017                    Estimated time to complete activity: 1.0 hours
Expiration date: January 17, 2018

Faculty

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center

Steve Malangone, MSN, FNP-C, AOCNP®
University of Arizona Cancer Center

Activity Rationale and Purpose
Globally, gastric cancer is the third leading cause of cancer death; however, in North America and most Western European countries, gastric cancer is a relatively rare diagnosis. Currently, outcomes are poor for patients with advanced gastric cancer: 5-year survival is only 4% for those with stage IV disease. In light of the poor outcomes associated with advanced stages of gastric and esophageal cancers, novel treatment approaches are highly desired. Emerging data regarding investigational agents suggest that this goal may soon be realized. Specifically, monoclonal antibodies that inhibit programmed cell death protein 1 (PD-1) are expected to improve management of both gastric and esophageal cancers by enhancing the body’s immune response. As clinical data emerge, it is critical for advanced practitioners (APs) and oncologists to be well versed in the efficacy, safety, and tolerability data associated with these new agents for the treatment of advanced gastric and esophageal cancers. 

Intended Audience
The intended audience for this enduring internet activity is physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists who specialize in the field of oncology.

Learning Objectives
After completing this educational activity, participants should be able to:

  • Effectively manage patients with advanced gastric cancers in a manner that facilitates improved patient outcomes
  • Anticipate and address treatment-related side effects associated with current and emerging novel therapies for advanced gastric cancers
  • Provide direct care for patients with advanced gastric cancers regardless of the practice setting (academic or community), including knowing when to refer patients from the community to a center with expertise in these tumor types
  • Explain the mechanism of action and potential role of emerging novel small molecules, antibodies, and immunotherapies, including PD-1 inhibitors, in the management of advanced gastric cancers

Continuing Education

Physicians

Annenberg Center for Health Sciences at Eisenhower

The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®)

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

A maximum of 1.0 contact hours may be earned for successful completion of this activity.

Pharmacists

Accreditation Council for Pharmacy Education

This knowledge-based accredited education lecture is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program
# 0797-9999-17-009-H04-P. This program is designated for up to 1.0 contact hours (0.1 CEUs) of continuing pharmacy educational credit.

Financial Disclosures
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Faculty

David H. Ilson, MD, PhD, has served as a consultant for Amgen, Bayer, Lilly/Imclone, and Pieris.

Steve Malangone, MSN, FNP-C, AOCNP® has acted as a consultant for Taiho Oncology.

Lead Nurse Planner
Wendy J. Smith ACNP, AOCN®, has nothing to disclose.

Planners
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.

Content Reviews
Wendy J. Smith ACNP, AOCN®, has nothing to disclose.

Annenberg Center for Health Sciences at Eisenhower
The staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclaimer
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Meniscus Educational Institute and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit
To access the learning assessment and evaluation form online, visit education.annenberg.net/jpl16-sessions.

Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment and complete and submit the evaluation form) will be able to download a statement of credit.

Credits & accreditation
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 Attendance
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 Attendance
Course opens: 
01/05/2017
Course expires: 
01/17/2018
Cost:
$0.00
Please login or register to take this course.